A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-945429 in Subjects with Moderate to Severe Crohn's Disease Revised Protocol 01, incorporating Amendment 02 (dated 20-Mar-12) + Pharmacogenetics Blood Sample Amendment 01

Trial Profile

A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-945429 in Subjects with Moderate to Severe Crohn's Disease Revised Protocol 01, incorporating Amendment 02 (dated 20-Mar-12) + Pharmacogenetics Blood Sample Amendment 01

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2016

At a glance

  • Drugs Clazakizumab (Primary) ; Clazakizumab (Primary)
  • Indications Crohn's disease
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Alder Biopharmaceuticals; Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 08 May 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 08 May 2013 Planned End Date changed from 1 Nov 2015 to 1 Sep 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top